Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mobenakin

Drug Profile

Mobenakin

Alternative Names: Interleukin-1 beta mutein; OCT 43

Latest Information Update: 15 Aug 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nonindustrial source
  • Developer Chiron Corporation; Otsuka Pharmaceutical
  • Class Interleukins
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Granulocyte macrophage colony stimulating factor agonists; Interleukin 1 inhibitors; Macrophage colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Glioma; Lymphoma; Urogenital cancer

Most Recent Events

  • 18 Feb 1997 Preregistration for Lymphoma in Japan (SC)
  • 20 Nov 1995 OCT 43 is now called mobenakin
  • 02 Nov 1995 Investigation in Glioma in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top